Journal
BIOENGINEERED
Volume 12, Issue 2, Pages 10366-10378Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21655979.2021.1996515
Keywords
Glioblastoma; immunotherapy; isocitrate dehydrogenase; prognostic value; programmed death ligand 1
Categories
Ask authors/readers for more resources
This meta-analysis found that increased PD-L1 expression is associated with poorer overall survival in patients with glioblastoma (GBM). The study also revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase (IDH). Overall, increased PD-L1 expression may serve as a promising prognostic biomarker for GBM.
Excellent prognostic value of programmed death ligand 1 (PD-L1) is observed in patients with other cancers; however, the prognostic value of PD-L1 in glioblastoma (GBM) remains unclear. Therefore, this meta-analysis evaluated the prognostic value of PD-L1 in GBM. We performed a systematic search in databases to screen eligible articles. The hazard ratio (HR) and 95% confidence interval (95% CI) were extracted from included articles. This meta-analysis included 15 studies, and the forest plot indicated that increased PD-L1 expression was associated with poorer overall survival (OS) of GBM (HR, 1.16; 95% CI, 1.05-1.27; P = 0.002). Furthermore, stratified analysis confirmed that PD-L1 expression was associated with unfavorable OS at the protein level (HR, 1.30; 95% CI, 1.13-1.48; P< 0.001) and messenger ribonucleic acid (mRNA) level (HR, 1.05; 95% CI, 1.00-1.09; P= 0.041). The analysis of a dataset verified the prognostic value of PD-L1 and revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase (IDH). In conclusion, increased PD-L1 expression predicts unfavorable OS in GBM and may be a promising prognostic biomarker of GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available